Klaus Rose

762 total citations
45 papers, 253 citations indexed

About

Klaus Rose is a scholar working on Pediatrics, Perinatology and Child Health, Economics and Econometrics and General Health Professions. According to data from OpenAlex, Klaus Rose has authored 45 papers receiving a total of 253 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pediatrics, Perinatology and Child Health, 15 papers in Economics and Econometrics and 10 papers in General Health Professions. Recurrent topics in Klaus Rose's work include Pharmaceutical studies and practices (33 papers), Ethics and Legal Issues in Pediatric Healthcare (15 papers) and Child and Adolescent Health (10 papers). Klaus Rose is often cited by papers focused on Pharmaceutical studies and practices (33 papers), Ethics and Legal Issues in Pediatric Healthcare (15 papers) and Child and Adolescent Health (10 papers). Klaus Rose collaborates with scholars based in United States, Slovenia and Switzerland. Klaus Rose's co-authors include Jane M. Grant‐Kels, Philip D. Walson, Matthias Kopp, Thomas Müller, Hans Kummer, Stephen Senn, David Neubauer, Oscar Della Pasqua, Rudolf Happle and Michael G. Spigarelli and has published in prestigious journals such as SHILAP Revista de lepidopterología, British Journal of Clinical Pharmacology and Clinical Therapeutics.

In The Last Decade

Klaus Rose

41 papers receiving 225 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Klaus Rose United States	10	195	56	48	34	27	45	253
Donato Bonifazi Italy	10	156 0.8×	71 1.3×	37 0.8×	5 0.1×	7 0.3×	24	299
Rachael Thorneloe United Kingdom	9	59 0.3×	45 0.8×	56 1.2×	164 4.8×	14 0.5×	13	310
Jacobo Pérez Spain	9	99 0.5×	16 0.3×	25 0.5×	17 0.5×	5 0.2×	13	267
Johan De Munter Belgium	5	100 0.5×	14 0.3×	23 0.5×	5 0.1×	52 1.9×	14	218
Annelieke Pasma Netherlands	8	35 0.2×	25 0.4×	19 0.4×	25 0.7×	3 0.1×	21	329
Jason Benedict United States	9	35 0.2×	11 0.2×	33 0.7×	15 0.4×	48 1.8×	43	271
Marta Murillo Spain	10	93 0.5×	18 0.3×	24 0.5×	35 1.0×	3 0.1×	20	325
Alice Jordan United Kingdom	7	53 0.3×	18 0.3×	51 1.1×	23 0.7×	46 1.7×	12	258
Joseph A. Picoraro United States	8	75 0.4×	5 0.1×	21 0.4×	29 0.9×	32 1.2×	29	265
Anupriya Agarwal Australia	5	33 0.2×	60 1.1×	53 1.1×	12 0.4×	110 4.1×	9	234

Countries citing papers authored by Klaus Rose

Since Specialization

Citations

This map shows the geographic impact of Klaus Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Rose more than expected).

Fields of papers citing papers by Klaus Rose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Rose. The network helps show where Klaus Rose may publish in the future.

Co-authorship network of co-authors of Klaus Rose

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Rose. A scholar is included among the top collaborators of Klaus Rose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Rose. Klaus Rose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Russo, Emilio, et al.. (2024). Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals. World Journal of Methodology. 14(2). 92371–92371. 1 indexed citations

Rose, Klaus, et al.. (2022). Neurology’s vital role in preventing unnecessary and potentially harmful pediatric studies. Expert Review of Neurotherapeutics. 22(3). 209–219. 1 indexed citations

Rose, Klaus, et al.. (2021). COVID-19 and Treatment and Immunization of Children—The Time to Redefine Pediatric Age Groups is Here. Rambam Maimonides Medical Journal. 12(2). e0010–e0010.

Rose, Klaus. (2020). Paediatric Oncology at the Crossroads: A Call for Change. Pharmaceutical Medicine. 34(5). 297–300. 3 indexed citations

Rose, Klaus, David Neubauer, & Jane M. Grant‐Kels. (2019). Too Many Avoidable Suicides Occur Worldwide in Young Patients. SHILAP Revista de lepidopterología. 10(4). e0026–e0026. 1 indexed citations

Rose, Klaus & Philip D. Walson. (2019). Are Regulatory Age Limits in Pediatric Melanoma Justified?. Current Therapeutic Research. 90. 113–118. 1 indexed citations

Rose, Klaus, David Neubauer, & Jane M. Grant‐Kels. (2019). Questionable Industry-Sponsored Postneonatal Pediatric Studies in Slovenia. Current Therapeutic Research. 90. 86–91. 3 indexed citations

Rose, Klaus. (2019). The Challenges of Pediatric Drug Development. Current Therapeutic Research. 90. 128–134. 21 indexed citations

Rose, Klaus & Jane M. Grant‐Kels. (2018). The Meanings of “Pediatric Drug Development”. Therapeutic Innovation & Regulatory Science. 53(6). 767–774. 11 indexed citations

10.

Rose, Klaus & Philip D. Walson. (2017). Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?. Pediatric Drugs. 19(6). 515–522. 9 indexed citations

11.

Rose, Klaus & Philip D. Walson. (2017). Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?. Clinical Therapeutics. 39(2). 253–265. 7 indexed citations

12.

Rose, Klaus & Philip D. Walson. (2015). The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia. Risk Management and Healthcare Policy. 8. 185–185. 7 indexed citations

13.

Rose, Klaus & Stephen Senn. (2014). Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee—adolescents’ melanoma as a paradigm. Pharmaceutical Statistics. 13(4). 211–213. 11 indexed citations

14.

Rose, Klaus & Oscar Della Pasqua. (2011). Development of Paediatric Medicines: Concepts and Principles. Handbook of experimental pharmacology. 205. 111–124. 9 indexed citations

15.

Rose, Klaus. (2009). Challenges in Pediatric Drug Development. Pediatric Drugs. 11(1). 57–59. 11 indexed citations

16.

Rose, Klaus. (2008). Ethical, Regulatory and Scientific Challenges in Paediatric Drug Development. Pharmaceutical Medicine. 22(4). 221–234. 11 indexed citations

17.

Rose, Klaus. (2007). Integration of Pediatric Aspects into the General Drug Development Process. PubMed. 123–134. 1 indexed citations

18.

Rose, Klaus. (2005). Better medicines for children – where are we now, and where do we want to be?. British Journal of Clinical Pharmacology. 59(6). 657–659. 6 indexed citations

19.

Rose, Klaus. (1978). Theorie der Aussenwirtschaft. 1 indexed citations

20.

Rose, Klaus. (1965). Theorie der internationalen Wirtschaftsbeziehungen. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact